Cargando…

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer

The remarkable complexity of cancer involving multiple mechanisms of action and specific organs led researchers Hanahan and Weinberg to distinguish biological capabilities acquired by cancer cells during the multistep development of human tumors to simplify its understanding. These characteristic ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Losson, Hélène, Schnekenburger, Michael, Dicato, Mario, Diederich, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274245/ https://www.ncbi.nlm.nih.gov/pubmed/27886118 http://dx.doi.org/10.3390/molecules21111608

Ejemplares similares

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
por: Losson, Hélène, et al.
Publicado: (2020)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs)
por: Mackmull, Marie-Therese, et al.
Publicado: (2015)

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)
por: Friedrich, Annabelle, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer
por: Kong, Yanjie, et al.
Publicado: (2022)

Curcumin―The Paradigm of a Multi-Target Natural Compound with Applications in Cancer Prevention and Treatment
por: Teiten, Marie-Hélène, et al.
Publicado: (2010)

Natural Compounds as Regulators of the Cancer Cell Metabolism
por: Cerella, Claudia, et al.
Publicado: (2013)

Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
por: Zou, Yi, et al.
Publicado: (2013)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Hybrid Curcumin Compounds: A New Strategy for Cancer Treatment
por: Teiten, Marie-Hélène, et al.
Publicado: (2014)

A Survey of Marine Natural Compounds and Their Derivatives with Anti-Cancer Activity Reported in 2010
por: Schumacher, Marc, et al.
Publicado: (2011)

Chromatin remodeling induced by histone deacetylase inhibitors (HDACis) in HeLa, NIH 3T3 and HepG2 cells
por: Felisbino, Marina B, et al.
Publicado: (2013)

Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure
por: Qiu, Xiaodi, et al.
Publicado: (2019)

Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer
por: Alzoubi, Samer, et al.
Publicado: (2016)

A Survey of Marine Natural Compounds and Their Derivatives with Anti-Cancer Activity Reported in 2011
por: Sawadogo, Wamtinga Richard, et al.
Publicado: (2013)

A Survey of Marine Natural Compounds and Their Derivatives with Anti-Cancer Activity Reported in 2012
por: Sawadogo, Wamtinga Richard, et al.
Publicado: (2015)

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells
por: Lernoux, Manon, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

A transcriptomic dataset used to derive biomarkers of chemically induced histone deacetylase inhibition (HDACi) in human TK6 cells
por: Cho, Eunnara, et al.
Publicado: (2021)

Venus Flytrap (Dionaea muscipula Solander ex Ellis) Contains Powerful Compounds that Prevent and Cure Cancer
por: Gaascht, François, et al.
Publicado: (2013)

Epigenetic Regulation of Host Defense Peptide Synthesis: Synergy Between Histone Deacetylase Inhibitors and DNA/Histone Methyltransferase Inhibitors
por: Whitmore, Melanie A., et al.
Publicado: (2022)

Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease
por: Chen, Jane Y., et al.
Publicado: (2013)

Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies
por: Pal, Dilipkumar, et al.
Publicado: (2023)

Correction: Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington’s Disease
Publicado: (2017)

Role of Natural Products in Modulating Histone Deacetylases in Cancer
por: Merarchi, Myriam, et al.
Publicado: (2019)

5-aza-2′-deoxycytidine-mediated c-myc Down-regulation Triggers Telomere-dependent Senescence by Regulating Human Telomerase Reverse Transcriptase in Chronic Myeloid Leukemia()
por: Grandjenette, Cindy, et al.
Publicado: (2014)

Plumbagin Modulates Leukemia Cell Redox Status
por: Gaascht, François, et al.
Publicado: (2014)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

High throughput screening identifies modulators of histone deacetylase inhibitors
por: Gaupel, Ann-Christin, et al.
Publicado: (2014)

Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates
por: Bouyahya, Abdelhakim, et al.
Publicado: (2022)

Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(R), 6(S), 1’(R), 6’(S), 11(R), 17(S)-Fistularin-3 and Bcl-2 Inhibitor Venetoclax
por: Florean, Cristina, et al.
Publicado: (2018)

Natural chalcones as dual inhibitors of HDACs and NF-κB
por: ORLIKOVA, B., et al.
Publicado: (2012)

HDACIs and the inhibition of invasive potential
por: Dent, Paul
Publicado: (2013)

Comparison of Different Histone Deacetylase Inhibitors in Attenuating Inflammatory Pain in Rats
por: Mao, Yu, et al.
Publicado: (2019)

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
por: Peters, Godefridus J., et al.
Publicado: (2020)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_1fr2h6ockfv8eg52906omm89p6